# Council Judge / Red-Team Report — PepCodex master audit

**Judge:** independent of Audits A, B, and C (did not write those packets).  
**Date:** 2026-09-02  
**Mode:** AUDIT ONLY. Evidence over votes.  
**Trees:** working copy `feat/scoring-and-freshness` @ freeze `f1b91e0`; production `https://www.pepcodex.com` (`main` on Vercel).  
**Jurisdiction treated as primary:** United States.

**Combined audit verdict: FAIL (80 / 100).**  
Pass requires ≥90, no auto-fail, 100% accessible inventory reconciled, status for material claims, a Judge disposition for every critical/high, and visible unknowns. That bar is not met. Cheapest repairs are in [SCORECARD.md](SCORECARD.md). Machine ledger: [DISPOSITIONS.json](DISPOSITIONS.json). Dissent: [DISSENT-LOG.md](DISSENT-LOG.md). Rejected items: [REJECTED.md](REJECTED.md).

A council majority does not establish truth. NCBI esummary, FDA pages fetched 2026-09-02, and live HTML do.

---

## 1. What was judged

Read (required): INPUTS.md, FROZEN-INVENTORY.md, INVENTORY-SUMMARY.json, RECONCILIATION.json; Audit A REPORT/FINDINGS/STATUS (COVERAGE counts); Audit B REPORT/FINDINGS/STATUS/OPPORTUNITIES/IMPRESSION-SYSTEM; Audit C REPORT/FINDINGS/CLINIC-VERIFICATION/AFFILIATE-MATRIX/PAID-LISTING-MODEL/OUTREACH-PLAYBOOK (STATUS first 80+ lines); live-recon REPORT/PROBES; regulatory REPORT/SOURCES; templates REPORT/SPREADER-CLAIMS.

Independently opened (not rubber-stamped):

- All three protocol MDX files and NCBI esummary for every protocol PMID.
- `DossierLayout.astro` DrugSchema + SafetyBanner hardcodes; `SafetyBanner.astro` defaults; `BaseLayout.astro` gtag vs CookieConsent; `vercel.json` X-Robots-Tag; `clinics/[city].astro` FAQ ternary; peptide-condition approval ternary; InteractionMatrix “safe”; four calculator MDX files; editorial-policy, advertising-policy, directory, clinics index; clinic `vitality-wellness-miami.mdx`; `anaheim.mdx`; `tb-500.mdx`; `ss-31.mdx`; `orforglipron.mdx`; `semaglutide-safety.mdx`; `melanotan-safety.mdx`; `glp1-safety-overview.mdx`; `bpc-157.mdx` meta; `aod-9604-vs-semaglutide.mdx` YAML leak; `cagrilintide-semaglutide-approval.mdx` (branch).
- Live: `/peptides/semaglutide`, `/peptides/orforglipron`, `/peptides/bpc-157`, `/blog/cagrilintide-semaglutide-approval`, `/blog/semaglutide-vs-tirzepatide-2026`.
- Official: FDA Foundayo 2026-04-01; FDA compounding safety-risks (content current 2026-04-22); FDA Forzinity 2025-09-19; WADA 2026 Prohibited List S0 extract; WADA 2026 Monitoring Program (semaglutide/tirzepatide markers); ClinicalTrials.gov NCT07437547.

Did not: edit the site; contact clinics; enroll in programs; submit forms; invent replacements for blocked GSC/GA4.

---

## 2. Inventory reconciliation and unexamined surfaces

Frozen totals: **1343 surfaces**; indexable expectation 1112; live sitemap 1057; intersection 1050; live-not-in-repo 7 blogs; repo-not-in-live 60 (49 blog, 10 peptide, 1 glossary).

| Auditor | INSPECTED | SAMPLED | INACCESSIBLE IDs | OMITTED | STATUS stamp |
|---|---:|---:|---:|---:|---|
| A | 252 (18.8%) | 1091 | 0 | 0 | INCOMPLETE (correct) |
| B | 71 (5.3%) | 1272 | 0 | 0 | INCOMPLETE (correct) |
| C | 137 (10.2%) | 1206 | 0 | 0 | **COMPLETE (rejected)** |

Every frozen `surface_id` has a coverage row in each auditor’s COVERAGE.json. That is **ID reconciliation**, not line-by-line inspection. Freeze required deep-read of named peptides, all 31 safety, all 36 guides, all 3 protocols, all 52 clinics, templates, trust pages. **B did not meet that mandate** (3/20 named peptides, 1/36 guides, 1/31 safety, 0/3 protocol bodies, 15/32 templates). **A met more of it** (protocols, 20 named dossiers, 31 safety claim-scan, 36 guides claim-scan, 52 clinic records). **C met the directory slice** (52/52 clinics, 60/60 cities) and sampled the rest via grep.

**Unexamined / under-examined material (must stay visible):**

1. **GSC / GA4 current metrics** — UNAVAILABLE (`invalid_rapt`). Historical 2026-07-24/25 figures are dated only.
2. **CrUX / Lighthouse / axe** — not run.
3. **Production `main` source tree** — inferred from live HTML/headers/sitemap, not a checkout.
4. **269 comparison bibliographies** — not PMID-resolved (A disclosed).
5. **46 source-packs / live TrialTable NCT drug-match** — not done except NCT07437547 (Judge: real BPC-157 trial).
6. **Khavinson cluster** — B flagged thin word counts; A did not re-resolve PMIDs this increment (lessons already record adjacent-compound citations).
7. **Live blogs not in this branch’s expected sitemap** — 7 LIVE-NOT-IN-REPO URLs. Only some probed. **Judge found a CRITICAL miss on a repo-not-in-live URL that is nonetheless live 200:** `/blog/cagrilintide-semaglutide-approval`.
8. **`src/pages/sponsors/`** — empty directory; no sponsor URL in inventory.
9. **Private CMS / affiliate dashboards / email** — none in repo.

C’s COMPLETE stamp is an auto-fail of the *combined packet* (completeness claimed despite inaccessible GSC/GA4). A and B did not make that error.

---

## 3. Chair-level rechecks (Judge, not inherited)

### 3.1 Protocol PMIDs vs NCBI esummary

**Do not accept “6/7 unrelated.”** See DISSENT-LOG D-001.

BPC-157+TB-500 (`PROTOCOL-1094`): **5/7 wholly unrelated, 1/7 on-topic mis-attribution (30915550 Gwyer 2019 review, stored as Sikiric 2018 animal with invented 10 mcg/kg doses), 1/7 correct (25415472 Chang 2014).** The stored human-rct “0.2–2.0 mg daily for 4 weeks” on PMID **7521621** (Laudico, Philippine cancer-pain) is fabricated. Disposition: **ACCEPT WITH REVISION**, still CRITICAL (`M-A001`).

CJC-1295+ipamorelin: 16352683 Teichman **KEEP**; 16352684 sequential vitamin-D paper **WRONG**; 9849822 Raun **KEEP**; four others unrelated. **ACCEPT** (`M-A002`).

GH combinations: 9849822 and 18981485 Nass **KEEP**; seven others trypanosome / neurodegeneration / corpus callosum / haemochromatosis / IOL / NMDA / tamoxifen-analog. **ACCEPT** (`M-A003`).

ProtocolLayout links `pubmed.ncbi.nlm.nih.gov/${pmid}` — wrong IDs are live authoritative links.

### 3.2 DossierLayout hardcoded fdaStatus / wadaStatus / DrugSchema legalStatus

Confirmed in source (`DossierLayout.astro` L432–433, L585–586) and **live HTML**:

- `/peptides/semaglutide`: chip **FDA Approved** plus banner **Not FDA Approved**, **WADA Prohibited**, “Not approved for human use by any regulatory agency”, “Limited human clinical trial data”.
- `/peptides/orforglipron`: **Investigational** plus the same three default warnings and Not FDA Approved / WADA Prohibited.

WADA 2026 List S0 **names BPC-157**. 2026 Monitoring Program lists **markers of semaglutide and tirzepatide** (not prohibited). The generic WADA Prohibited stamp is false for Ozempic/Wegovy. **ACCEPT** (`M-REG-HARDCODE`).

SafetyBanner defaults fire because `keyWarnings` is empty and `[slug].astro` never passes `safetyInfo`. **ACCEPT**.

### 3.3 Clinic example.com + verifiedListing

`INVENTORY-SUMMARY`: 52 placeholder websites, 50 `verifiedListing: true`. File `vitality-wellness-miami.mdx`: `https://example.com/vitality-wellness`, `(305) 555-0100`, `featured: true`, `verifiedListing: true`, “board-certified physicians”, BPC-157 on the menu. Pattern holds across the collection. **ACCEPT** (`M-CLINIC-FAKE`, `M-VERIFIED-BADGE`).

### 3.4 City FAQ “multiple” when count is 0

`src/pages/clinics/[city].astro` L50: `` `${name} has ${cityClinics.length > 0 ? cityClinics.length : 'multiple'} peptide therapy clinics` ``. `anaheim.mdx` has no matching clinic record and still says “verified providers.” Twelve empty cities. FAQPage JSON-LD ships on noindex pages. **ACCEPT** (`M-CITY-FAQ`).

### 3.5 Foundayo NDA 220934 2026-04-01 vs live orforglipron

FDA press 2026-04-01: Foundayo (orforglipron) approved; NME; weight management, not described as T2D; titration 0.8 → 2.5 → 5.5 then 9 / 14.5 / **17.2 mg**; boxed warning thyroid C-cell / MTC / MEN2; do not combine with another GLP-1RA.

Live `/peptides/orforglipron`: Investigational, NDA submitted, ATTAIN-1 **36 mg**, Not FDA Approved banner, quality checklist 12/24/36 mg, no boxed warning.

Working-tree `orforglipron.mdx` `regulatoryStatus` already records Foundayo NDA 220934 1 Apr 2026; aliases still omit Foundayo; checklist still 36 mg. **ACCEPT** (`M-ORFORGLIPRON`).

### 3.6 Sitewide X-Robots-Tag vs HTML noindex

`vercel.json` `/(.*)` → `X-Robots-Tag: index, follow`. Live-recon: every sampled 200, including `/clinics/new-york` and `/glossary/autophagy` (HTML `noindex, follow`). Google’s more-restrictive-wins rule is not a reason to leave the header wrong. **ACCEPT** (`M-XROBOTS`).

### 3.7 GA gtag in BaseLayout before CookieConsent

This-branch `BaseLayout.astro` injects `gtag('config')` in `<head>` whenever `PUBLIC_GA_TRACKING_ID` is set. `CookieConsent` is at the end of `<body>` and may then `consent default denied`. Live homepage: static `gtag/js?id=G-1M56CNL8CK` + inline config in head, cookie dialog later, no `consent default` before config. Vercel Analytics ungated. Whether a collect hit left the browser is **UNVERIFIABLE** (no JS runtime). Source-order defect is FACT. **ACCEPT** (`M-GA-CONSENT`).

### 3.8 Working tree ≠ production

Confirmed, not a slogan. Live dossier titles (95 / 42 studies), llms.txt 2026-02-18, tesamorelin calculator 200, orforglipron still investigational, CagriSema blog still “FDA approved.” Branch has different counts, Foundayo notes, 301s that production does not apply, and a rewritten CagriSema body that is **not** what Googlebot would fetch today.

---

## 4. Judge-owned finding the three audits missed

**`M-LIVE-CAGRISEMA` — CRITICAL — ACCEPT**

Live `https://www.pepcodex.com/blog/cagrilintide-semaglutide-approval` (GET 2026-09-02):

- Title: “CagriSema FDA Approved: What It Means (2025)”
- Body: “The U.S. Food and Drug Administration has approved CagriSema…”
- REDEFINE-1 quoted as **22.7%** at 68 weeks (press-release / efficacy-style figure).
- “Sources” are PubMed *search* links, not papers.

Working-tree `src/content/blog/cagrilintide-semaglutide-approval.mdx` `lastUpdated: 2026-09-02` says **under FDA review, not approved**, REDEFINE 1 treatment-policy **20.4%**, PMID 40544433.

Regulatory pack: Novo NDA **filed** 2025-12-18; **not** on FDA Novel Drug Approvals 2026 through 2026-08-28.

Frozen RECONCILIATION lists this URL under **repo-not-in-live** (absent from the 1057-URL sitemap). It is still HTTP **200**. Sitemap absence is not unpublish.

This is an unsupported medical-regulatory claim on production. It is also an **undisclosed coverage gap** in A/B/C FINDINGS (the URL appears as an IA mismatch, not as a false-approval CRITICAL). Auto-fail trigger.

Same-class cheap follow-up (not done by A/B/C, not fully done here): live-GET other title-overclaim blogs (`pemvidutide-eu-mash-approval`, `pemvidutide-crl-more-data`, `survodutide-fda-submission-mash`, `wegovy-pill-launches-us`, `fda-semaglutide-shortage-extended`). Regulatory pack already notes filename/title debt vs corrected bodies **in this branch**. Production may still serve the old bodies.

---

## 5. Dispositions of every critical / high (merged)

Full rows: DISPOSITIONS.json. Summary:

| Merged | Sources | Sev | Disposition |
|---|---|---|---|
| M-A001 | A-001 | CRITICAL | ACCEPT WITH REVISION (count) |
| M-A002 | A-002 | CRITICAL | ACCEPT |
| M-A003 | A-003 | CRITICAL | ACCEPT |
| M-REG-HARDCODE | A-004, A-005, A-023, B-002 | CRITICAL | ACCEPT |
| M-CLINIC-FAKE | A-006, C-001, C-005 | CRITICAL | ACCEPT |
| M-VERIFIED-BADGE | C-002, A-016 | CRITICAL | ACCEPT |
| M-CITY-FAQ | A-007, B-003, C-003 | CRITICAL | ACCEPT |
| M-LIVE-CAGRISEMA | JUDGE | CRITICAL | ACCEPT |
| M-COMPOUND-MENUS | A-008, C-007 | HIGH | ACCEPT WITH REVISION (Cat 2 table) |
| M-SOURCING | A-009 | HIGH | ACCEPT |
| M-ORFORGLIPRON | A-010 | HIGH | ACCEPT |
| M-CALCULATOR | A-011, B-011 | HIGH | ACCEPT WITH REVISION (action split) |
| M-TB500 | A-012 | HIGH | ACCEPT |
| M-BPC-TIMELINE | A-013 | HIGH | ACCEPT WITH REVISION (NCT07437547 is real) |
| M-SEMA-SAFETY | A-014 | HIGH | ACCEPT |
| M-MELANOTAN | A-015 | HIGH | ACCEPT |
| M-EDITORIAL | A-017 | HIGH | ACCEPT |
| M-SS31 | A-018 | HIGH | ACCEPT WITH REVISION (notes already Barth-only) |
| M-LIVE-REPO | A-020, B-007 | HIGH | ACCEPT |
| M-XROBOTS | B-001 | HIGH | ACCEPT |
| M-COMPARISONS | B-004 | HIGH | ACCEPT |
| M-PC-THIN | B-005 | HIGH | ACCEPT |
| M-PC-APPROVAL | JUDGE, templates | HIGH | ACCEPT |
| M-BLOG-GUIDE | B-006 | HIGH | ACCEPT |
| M-BPC-META | B-012 | HIGH | ACCEPT |
| M-GA-CONSENT | B-014 | HIGH | ACCEPT |
| M-EEAT | B-015 | HIGH | ACCEPT |
| M-THIN-PEPTIDES | B-022 | HIGH | ACCEPT |
| M-SURMOUNT | B-025 | HIGH | ACCEPT WITH REVISION (22.5% on-page confirmed; estimand label) |
| M-FEATURED | C-004 | HIGH | ACCEPT |
| M-FTC | C-006 | HIGH | NEEDS EXPERT REVIEW (legal mapping) |
| M-GOOGLE-SPAM | C-008 | HIGH | ACCEPT |
| M-CREDENTIALS | C-015 | HIGH | ACCEPT |
| M-OUTREACH | C-018 | HIGH | ACCEPT |

No critical/high was rubber-stamped. Two HIGH legal-mapping rows are NEEDS EXPERT REVIEW (FTC Rule-as-applied, telehealth 50-state). Underlying fake-listing facts are ACCEPT elsewhere.

---

## 6. Sample of remaining (non-critical/high) findings

Required ≥20% of remaining. Remaining unique medium/low after merge ≈ 28. Judge sampled **12 (43%)** and expanded after two recurring error classes (count inflation; Category-2 vs withdrawn).

| Sampled | Result |
|---|---|
| A-019 / B-013 / C-009 directory Coming Soon + verified | ACCEPT. `directory.astro` still promises a curated verified list. |
| A-021 ileus “under review” | ACCEPT. File still says Under review for ileus **and** aspiration. |
| A-022 nausea inconsistency | ACCEPT. Live 30–45% vs safety 15–20%. |
| B-008 logo.png 404 | ACCEPT (live-recon). |
| B-010 Spring 2026 / canonical slash | ACCEPT (live homepage). |
| B-021 study-count titles | ACCEPT; compounded by live 95 vs repo 67. |
| B-026 Miami premier copy | ACCEPT as doorway language on noindex pages. |
| C-010 FormSubmit | ACCEPT (processor unnamed; captcha false). |
| C-013/C-014 orphans + count bug | ACCEPT. |
| C-016 policy vs directory | ACCEPT. |
| C-020 no dossier clinic CTA leak | ACCEPT (positive on dossiers). |
| B-004 YAML leak (via comparison file, not only JSON) | ACCEPT. `aod-9604-vs-semaglutide.mdx` metaDescription contains `>- Citations and data reviewed.` |

Recurring errors → expand: A-001 report vs FINDINGS count; C-007 Category 2 membership. Both revised, not used to discard the underlying defects.

Medium/low ACCEPT unless noted: M-DIRECTORY-SOON, M-GLP1-CLASS, M-NAUSEA, M-HOMEPAGE-BPC (WITH REVISION), M-BPC-GUIDE, M-LOGO, M-LLMS, M-HOME-CANONICAL, M-FDA-NOTICE (WITH REVISION), M-GRAPH, M-SITEMAP, M-A11Y, M-BREADCRUMB, M-SEMA-TITLE, M-ROBOTS-TXT, M-FILTERS, M-MIAMI, M-404, M-HOWTO, M-GLOSSARY-NOINDEX, M-APP-CTA, M-CONDITIONS, M-REDIRECTS, M-FORMSUBMIT, M-NO-PROCESS, M-CLINIC-SCHEMA, M-ORPHANS, M-POLICY, M-CITY-COPY, M-AFFILIATE, M-NO-LEAK, M-MK677, M-SAFE-COMBINE.

NEEDS EXPERT REVIEW: M-PRIVACY-SCOPE, M-FTC (legal mapping only), M-TELEHEALTH.

REJECT of a *finding*: none of the site-defect rows. REJECT of process/opportunity claims: REJECTED.md (C COMPLETE stamp, 6/7 count, live Cat-2 membership for BPC-157, reindex clinics, RUO affiliates, extra calculators, “BPC now legal”).

---

## 7. Citation / source-support checks

Opened sources supported the **exact** attributed claim except where revised:

- Protocol PMIDs: titles do **not** support stored authors/doses except Chang 25415472, Teichman 16352683, Raun 9849822, Nass 18981485.
- STEP 1 14.9% on live semaglutide and live comparison blog matches the well-known Wilding NEJM paper (PMID 33567185) — A’s evidence ledger on that point holds; Judge did not re-extract the table.
- Foundayo approval, dose range, boxed warning: FDA press supports A-010 / regulatory pack.
- Forzinity Barth-only accelerated approval: FDA press supports A-018’s *qualifier*, not a claim that the dossier notes are empty.
- FDA compounding page supports **withdrawn-table** language for BPC-157, not live Category 2 membership.
- NCT07437547 supports a real BPC-157 hamstring RCT, contradicting any implication it is a fake ID.
- Live CagriSema “FDA approved” is **contradicted** by FDA novel-drug list + Novo filing + this-branch rewrite.

Citation laundering: protocol pages launder unrelated PMIDs as human RCTs. Live CagriSema “sources” launder PubMed *search URLs* as citations. Editorial policy “every cited source is verified to represent the claim” is contradicted by both.

Jurisdiction: US FDA/FTC/WADA used where the page claims US facts. No EU MDR/UK MHRA assumed.

Outdated: live orforglipron (five months after Foundayo); live CagriSema approval post; GLP-1 class safety January 2026; BPC meta “no human trials”; llms.txt February 2026; homepage Spring 2026.

Commercial bias in *audits*: not found. C rejected RUO affiliates and forbade paying for Verified. Site Featured ribbon is unlabeled ranking on fake clinics — reported, not concealed.

Overconfident language in *audits*: A-001 “6/7”; C-007 “Category 2” as current membership; C COMPLETE. Revised.

Hypotheses as facts in *audits*: B-016/A-024 labeled weaker. C-006 over-maps listings onto the Fake Reviews Rule — NEEDS EXPERT REVIEW. Graph silent=1111 as indexation — rejected as current fact.

---

## 8. Opportunities (blog / SEO / directory)

B’s 25 opportunities default to **refresh / merge / noindex**. That matches INPUTS.md crawl-budget constraint. Judge **rejects** (REJECTED.md): reindex cities, extra calculators, RUO affiliates, “BPC now legal,” HowTo on reconstitution, `/app` doorway, pay-for-Verified.

**Accept as URL reduction only:** collapse 36 blog/guide pairs; 301 thin comparisons; canonicalize semaglutide-vs-tirzepatide to the comparison URL; Foundayo card on the **existing** orforglipron dossier; 503A-vs-withdrawal on existing BPC/FDA-notice pages.

Directory is **not** an opportunity until placeholders are gone. C’s paid-listing model is an ethical draft **after** quarantine; payment must never buy Verified, grades, or organic rank. Outreach playbook is **DRAFT — NOT SENT** and correctly forbids using the 52 names.

---

## 9. Residual risks (not fully closed)

1. Other production blogs whose filenames imply approval/CRL/shortage may still serve old bodies (same class as M-LIVE-CAGRISEMA).
2. Source-pack / TrialTable NCT drug-match across live semaglutide (many NCT07x). NCT07437547 passed; that does not clear the table.
3. Comparison FAQ schema Q&A not in visible body (live-recon Page D) — medical numbers in JSON-LD only.
4. `Access-Control-Allow-Origin: *` on live HTML (live-recon); not in this-branch vercel.json — residual, LOW, not independently traced to a Vercel dashboard.
5. Whether Featured ever took money — UNVERIFIABLE.
6. PCAC vote tally / 503B bulks final / CagriSema FDA decision — UNKNOWN.
7. DailyMed full labels — DNS failed; boxed-warning quotes from FDA press/PDFs.
8. gtag network hit before consent — HTML source only.
9. Khavinson adjacent-compound citations — integrity class known, not re-resolved this pass.
10. Shipping this branch would 301 currently indexed live URLs **and** still ship 36 mg “dosing instructions” and Sourcing checklists unless those are fixed first.

---

## 10. Strongest / weakest / blind spot (Judge)

**Strongest confirmed cluster:** live false regulatory banners on approved drugs **plus** three protocol pages of wrong PMIDs **plus** a 52-row fictional Verified directory **plus** a live “FDA approved CagriSema” post. That is YMYL integrity failure independent of traffic.

**Weakest accepted finding:** A-024 homepage prominence of BPC-157 (product choice, not a false number).

**Blind spot the audits under-weighted:** production HTML for **blogs that this branch already rewrote**. Auditing `feat/scoring-and-freshness` MDX is not auditing pepcodex.com. The CagriSema page is the proof.

---

## 11. Scorecard and auto-fail

See [SCORECARD.md](SCORECARD.md). **80/100 FAIL.**

Auto-fail fired:

- Completeness claimed despite inaccessible GSC/GA4 (`audit-c/STATUS.txt` COMPLETE).
- Undisclosed coverage gap: live CagriSema false approval not in FINDINGS as CRITICAL.

No auditor fabricated a citation. No outreach was sent. Affiliates were not enrolled. Payment-for-rank is flagged, not hidden.

---

## 12. Cheapest repairs (do not lower the standard)

1. C STATUS.txt → INCOMPLETE.  
2. A-001 report count → 5 unrelated + 1 mis-attributed + 1 correct.  
3. C-007 → withdrawn table vs live Category 2 (FDA 2026-04-22).  
4. Add M-LIVE-CAGRISEMA to the ledger (already in this Judge packet) and treat production unpublish of that URL as P0.  
5. Live-GET remaining title-overclaim blogs; record live vs branch.  
6. Stamp WADA 2026 List/Monitoring Program as opened (done here).

Then re-score. Do not claim 90 until 1–5 are in the auditors’ own files, not only in council/.

---

## 13. Unknowns (do not invent)

GSC/GA4 current; CrUX; production SHA; PCAC votes; 503B bulks final; CagriSema FDA decision; Featured payment; DailyMed HTML; gtag first-hit; remaining live-blog bodies; whether 60 repo-not-in-live URLs 404 or 200.

Judge STATUS: **COMPLETE** (this assignment). Combined site audit: **INCOMPLETE and FAIL**.
